A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women
A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women
The primary objective of this study is to evaluate the efficacy of a regimen containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) versus ritonavir (RTV)-boosted atazanavir (ATV/r) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in HIV-1 infected, antiretroviral treatment-naive adult women.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Los Angeles, California 90033, United States
Washington D.C., District of Columbia 20037, United States
Chapel Hill, North Carolina 27599, United States
Greenville, North Carolina 27834, United States
Philadelphia, Pennsylvania 19140, United States
Barnaul, 656010, Russia
Irkutsk, 664043, Russia
Khabarovsk, 680031, Russia
Krasnodar, 350015, Russia
Krasnoyarsk, 660049, Russia
Lipetsk, 398043, Russia
Moscow, 105275, Russia
Moscow, 129110, Russia
Nizhny Novgorod, 603950, Russia
Oryol, 302040, Russia
Saint Petersburg, 190020, Russia
Saint Petersburg, 190103, Russia
Saint Petersburg, 191167, Russia
Saint Petersburg, 196645, Russia
Saratov, 410009, Russia
Volgograd, 400040, Russia
Voronezh, 394065, Russia
Yekaterinburg, 620102, Russia
Bangkok, 10700, Thailand
London, WC1E 6JB, United Kingdom